1. Introduction {#sec1-jcm-08-01835}
===============

Chronic Obstructive Pulmonary Disease (COPD) is a common disease, which is characterized by a persistent expiratory airflow limitation that is usually progressive \[[@B1-jcm-08-01835]\]. Exacerbations of respiratory symptoms frequently occur in COPD patients and are triggered by environmental pollutants, respiratory infections with bacteria or viruses, and unknown factors \[[@B1-jcm-08-01835]\]. Inhaled β~2~-receptor agonists are one of the main classes of bronchodilators used to treat airflow obstruction \[[@B1-jcm-08-01835]\]. The β~2~-adrenergic receptor is a member of the G protein-coupled transmembrane receptors widely located on airway smooth muscle cells that mediate relaxation and thus bronchodilation \[[@B2-jcm-08-01835],[@B3-jcm-08-01835]\], and therefore is an important drug target in COPD treatment. The gene encoding the β~2~-adrenergic receptor, *ADRB2*, is a small intron-less gene on chromosome 5q31-32 \[[@B2-jcm-08-01835]\]. Multiple single nucleotide polymorphisms (SNPs) in this gene have been described \[[@B2-jcm-08-01835]\]. Two of these SNPs code for amino acid changes at positions 16 \[arginine to glycine (16Arg \> Gly); rs1042713\] and 27 \[glutamine to glutamic acid (27Gln \> Glu); rs1042714\], both of which are common variants and have previously been studied \[[@B4-jcm-08-01835],[@B5-jcm-08-01835]\].

There is inconsistent evidence from previous studies on the association between *ADRB2* polymorphisms and treatment response to inhaled β~2~-agonists on COPD exacerbations \[[@B6-jcm-08-01835],[@B7-jcm-08-01835],[@B8-jcm-08-01835]\], short-term bronchodilator response (BDRs) \[[@B9-jcm-08-01835],[@B10-jcm-08-01835]\], and long-term changes in forced expiratory volume in 1 s (FEV1) in patients with COPD \[[@B10-jcm-08-01835]\]. In addition, most studies assessed the effect of each SNP in isolation but not the combined effect of their haplotypes.

In this study, our main objective was to investigate whether two functional SNPs of the *ADRB2* gene, rs1042713 (16Arg \> Gly) and rs1042714 (27Gln \> Glu), and their haplotypes were associated with risk of exacerbations in COPD patients treated with inhaled β~2~-agonists.

2. Methods {#sec2-jcm-08-01835}
==========

2.1. Setting and Study Population {#sec2dot1-jcm-08-01835}
---------------------------------

The current study was conducted using data from the Rotterdam Study, an ongoing prospective population-based cohort study among inhabitants of the Ommoord district of Rotterdam, the Netherlands. The rationale and design of the Rotterdam Study have been described elsewhere \[[@B11-jcm-08-01835]\]. The Rotterdam Study (RS) includes three sub-cohorts RS-I, RS-II, and RS-III. Baseline data were collected from 1989 to 1992 in RS-I (*n* = 7983), from 2000 to 2003 in RS-II (*n* = 3011), and from 2006 to 2009 in RS-III (*n* = 3932). Follow-up examinations were conducted periodically, which consisted of a home interview and an extensive set of tests at the research facility. In addition, the data from the medical records of the general practitioners (GPs), nursing homes, and hospitals were collected. The Medical Ethics Committee of the Erasmus Medical Center approved the Rotterdam Study, and written consent was obtained from all participants. The study population for our analysis consisted of all participants with COPD who gave informed consent for follow-up monitoring and had pharmacy, genetic, and covariables data available until 1 January 2011.

2.2. COPD and COPD Exacerbations {#sec2dot2-jcm-08-01835}
--------------------------------

The diagnosis of COPD was confirmed by pre-bronchodilator obstructive spirometry (forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) \< 0.7) \[[@B12-jcm-08-01835]\]. In case spirometry was uninterpretable, COPD cases were diagnosed by a physician based on clinical history, physical examination, and spirometry \[[@B12-jcm-08-01835]\]. COPD diagnosed prior to study start was defined as prevalent COPD, and incident COPD was defined as the first diagnosis of COPD during follow-up.

Subjects were followed from cohort entry or the date of COPD diagnosis (incident COPD) until the first COPD exacerbation, death, lost to follow-up, or the end of the study period (i.e., 1 January 2011), whichever came first. A moderate COPD exacerbation was defined as an acute episode of worsening of COPD symptoms requiring a course of systemic corticosteroid and/or antibiotics \[[@B13-jcm-08-01835]\]. If a patient was hospitalized because of COPD exacerbation, it was classified as a severe COPD exacerbation \[[@B13-jcm-08-01835]\]. The first COPD exacerbation was defined as the outcome of interest and the date of outcome was taken as the index date.

2.3. Drug Exposure {#sec2dot3-jcm-08-01835}
------------------

Medication dispensing data were obtained from the computerized pharmacies in the study district. Records of all filled prescriptions from 1 January 1991 onwards were available and included information on the product name, the Anatomical Therapeutic Chemical Classification (ATC) codes \[[@B14-jcm-08-01835]\], the dispensing date, the prescribed dosing regimen, and the amount dispensed. The studied β~2~-agonists inhalers comprised of (i) short-acting β~2~-agonists (SABA): salbutamol either in monotherapy (R03AC02) or as a fixed-dose combination with ipratropium bromide (R03AL02), terbutaline (R03AC03), fenoterol either in monotherapy (R03AC04) or as a fixed-dose combination with ipratropium bromide (R03AL01), and (ii) long-acting β~2~-agonists (LABA): salmeterol either in monotherapy (R03AC12) or as a fixed-dose combination with fluticasone (R03AK06), formoterol either in monotherapy (R03AC13) or as a fixed-dose combination with budesonide (R03AK07) or with beclometasone (R03AK08). The newer β~2~-agonists inhalers like indacaterol or olodaterol either in monotherapy or as a fixed-dose combination with inhaled corticosteroid (ICS) were not yet available on the Dutch market at the time the study was conducted. To investigate a dose-response relationship, the prescribed daily dose of each β~2~-agonist was expressed in standardized defined daily doses according to the ATC/DDD-stem of the World Health Organization (DDDs) \[[@B14-jcm-08-01835]\]. Patients were considered as "current users" if they used a β~2~-agonist on the index date or when the last use of β~2~-agonists fell within 14 days prior to the index date. If the date of last use of β~2~-agonists was more than 14 days prior to the index date, subjects were considered as "past users". Patients were considered as "non-users" if they had never used β~2~-agonists prior to the index date during the study period. Data on ICS use, as monotherapy and/or fixed-dose combination with LABA, were extracted from pharmacy records with ATC codes (R03BA, R03AK06, R03AK07, and R03AK08). ICS users were compared to non-users as a reference group.

2.4. Genotyping {#sec2dot4-jcm-08-01835}
---------------

Subjects in RS were genotyped with Illumina 500 (+duo) and Illumina Human 610-Quad BeadChips. The quality control (QC) procedures were applied. The genotype data were imputed with the 1000-Genomes reference panel (phase 1, V.3) using MACH V.1.0.15/1.0.16. We extracted genotype dosages for two SNPs rs1042713 (16Arg \> Gly) and rs1042714 (27Gln \> Glu) within the *ADRB2* gene. Imputation quality for both SNPs was high (\>0.99).

2.5. Functional Annotation of Variants and Expression Quantitative Trait Loci (eQTL) Analysis {#sec2dot5-jcm-08-01835}
---------------------------------------------------------------------------------------------

We retrieved all proxy SNPs in high linkage disequilibrium (LD) (*r*^2^ threshold \> 0.8, limit distance 100 kb, and population panel CEU) with the *ADRB2* variants; rs1042713 and rs1042714. For the functional annotation of the variants, we checked their predicted functions, including effects on gene regulation, protein structure, and splicing by using the HaploRegv4.1 (<https://www.broadinstitute.org/mammals/haploreg/haploreg.php>) \[[@B15-jcm-08-01835]\]. The correlation of the SNPs and its proxies in high LD with the expression level of the *ADRB2* gene in whole blood was checked using expression quantitative trait loci (eQTL) data from GeneNetwork \[[@B16-jcm-08-01835]\].

2.6. Covariables {#sec2dot6-jcm-08-01835}
----------------

Covariables consisted of age, sex, smoking, use of ICS, and the daily dose of β~2~-agonists. Data on smoking were obtained from questionnaires and were categorized into "never" or "ever-smokers". Further details are described in the [Supplementary Methods](#app1-jcm-08-01835){ref-type="app"}.

2.7. Systematic Review {#sec2dot7-jcm-08-01835}
----------------------

We conducted an extensive electronic literature search of Embase, Medline Ovid, and Cochrane Central using multiple search terms ([Supplementary Table S1](#app1-jcm-08-01835){ref-type="app"}) to identify all articles investigating the association between the *ADRB2* polymorphisms of interest, namely rs1042713 and/or rs1042714 and the risk of COPD exacerbation in patients treated with inhaled β~2~-agonists. Our literature search was restricted to studies published in English from inception until 30 September 2019. Further details are described in the [Supplementary Methods](#app1-jcm-08-01835){ref-type="app"}.

2.8. Statistical Analysis {#sec2dot8-jcm-08-01835}
-------------------------

Cox proportional hazards models were used to calculate hazard ratios (HRs) and their 95% confidence intervals (CIs) to analyze the association between each polymorphism of the *ADRB2* gene (as well as their haplotypes) and time to first COPD exacerbation. The exposure status to inhaled β~2~-agonists was analyzed as a time-dependent variable \[[@B17-jcm-08-01835]\]. The model estimates the exposure status of the case to inhaled β~2~-agonists on the event date (index date) and the exposure status of all other participants in the cohort on the same date of follow-up \[[@B17-jcm-08-01835]\]. Thus, each stratum consisted of one case and all other cohort participants who were event-free on the index date and still in follow-up \[[@B17-jcm-08-01835]\]. To account for potential confounding by indication, we stratified the study population into three categories, namely current users, past users, and non-users as defined in the methods section. An additive genetic model was assumed for the analysis. For SNPs analyses, we included rs1042713 and rs1042714 separately in the models and adjusted for age, sex, and smoking in the total cohort of COPD patients. In the categories of non-users and past users of β~2~-agonists, we adjusted for age, sex, ICS use, and smoking. The model was further adjusted for the daily dose of β~2~-agonists as a continuous variable in the category of current users.

The Haploview 4.2 \[[@B18-jcm-08-01835]\] was used to estimate haplotypes frequencies and linkage disequilibrium (LD) between two SNPs. The haplo.stats package \[[@B19-jcm-08-01835]\] (version 1.7.7) for R was applied to analyze the association between haplotypes and COPD exacerbations. The statistical methods of the haplo.stats package assume that all subjects are unrelated and linkage phase of the genetic markers is unknown \[[@B19-jcm-08-01835]\]. The haplo.design function \[[@B19-jcm-08-01835]\] was used to calculate haplotype effects for the haplotypes: Arg16/Gln27 and Gly16/Gln27 in reference to the baseline effect of the most frequent haplotype (Gly16/Glu27).

Most studies evaluated the effect of polymorphisms of the *ADRB2* gene among COPD patients with a smoking history. Hence, we investigated the association in ever-smokers. Sensitivity analyses were performed to evaluate the effect of *ADRB2* polymorphisms in the strata of current users of SABA only and LABA only. Because two SNPs (rs1042713 and rs1042714) were investigated, a Bonferroni-corrected P-value lower than 2.5 × 10^−2^ (0.05/2) was considered statistically significant. The data were analyzed using the SPSS statistical software version 24 (IBM SPSS Statistics for Windows; IBM Corp, Armonk, NY, USA) and R package (version 3.3.3) for haplotype analysis using the haplo.stats.

3. Results {#sec3-jcm-08-01835}
==========

3.1. Characteristics of the Study Population {#sec3dot1-jcm-08-01835}
--------------------------------------------

The study flow of participants is described in the [Supplementary Figure S1](#app1-jcm-08-01835){ref-type="app"}. [Table 1](#jcm-08-01835-t001){ref-type="table"} shows the baseline characteristics of the study population. The mean age (± SD) was 69.6 ± 9.0 years and 57.1% of subjects were male. At the end of follow-up, 80.0% of the study population (*n* = 842) had at least one COPD exacerbation. The minor allele frequencies for rs1042713 (Arg) and rs1042714 (Glu) were 0.35 and 0.47, respectively. Both SNPs were in Hardy-Weinberg equilibrium and they showed an LD with *r*^2^ = 0.47 (D′ = 1). Three haplotypes were determined at positions 16 and 27, and haplotype frequencies were as follows: Gly16/Glu27 (0.48), Arg16/Gln27 (0.35), and Gly16/Gln27 (0.17).

3.2. Association of ADRB2 Polymorphisms and COPD Exacerbations {#sec3dot2-jcm-08-01835}
--------------------------------------------------------------

In current β~2~-agonist users, the risk of COPD exacerbation decreased by 30% (HR: 0.70, 95% CI; 0.59--0.84) for each copy of the Arg allele of rs1042713 and by 20% (HR: 0.80, 95% CI; 0.69--0.94) for each copy of the Gln allele of rs1042714 in the adjusted models ([Table 2](#jcm-08-01835-t002){ref-type="table"}). The rs1042713 and rs1042714 polymorphisms were not associated with the risk of COPD exacerbation in the total cohort of COPD patients (irrespective of β~2~-agonists use) as well as in non-users and past users of inhaled β~2~-agonists ([Table 2](#jcm-08-01835-t002){ref-type="table"}).

To explore the combined effect of the two SNPs, we performed haplotype analysis ([Figure 1](#jcm-08-01835-f001){ref-type="fig"}). In the adjusted model, current β~2~-agonist users carrying the Arg16/Gln27 haplotype had a reduced risk of COPD exacerbation (HR: 0.70, 95% CI; 0.59--0.85) compared to the Gly16/Glu27 haplotype. No protective effect of the Gly16/Gln27 haplotype on COPD exacerbation could be observed ([Figure 1](#jcm-08-01835-f001){ref-type="fig"}).

Haploreg v4.1 data showed that rs1042713 and rs1042714 have no non-synonymous proxy variants in strong LD (*r*^2^ \> 0.8) ([Supplementary Tables S2 and S3](#app1-jcm-08-01835){ref-type="app"}). Moreover, the cis-eQTL data form GeneNetwork showed that the Arg allele (A) of rs1042713 and the Gln allele (C) of rs1042714 are associated with reduced levels of the *ADRB2* gene in whole blood \[[@B16-jcm-08-01835]\].

3.3. Sensitivity Analyses {#sec3dot3-jcm-08-01835}
-------------------------

We repeated the analysis by excluding never-smokers from our cohort of current users of β~2~-agonists ([Table 3](#jcm-08-01835-t003){ref-type="table"} and [Figure 2](#jcm-08-01835-f002){ref-type="fig"}). The results of SNPs and haplotypes analyses remained statistically significant and with similar risk estimates as for the main analyses. When we performed the analysis in strata of current users of SABA only and LABA only, we observed a statistically significantly reduced risk of COPD exacerbations per copy of the Arg allele of rs1042713 among current users of SABA ([Table 4](#jcm-08-01835-t004){ref-type="table"}). In the LABA only treatment category, we observed a similar trend as in the main analysis; however, the estimates lacked statistical significance ([Table 4](#jcm-08-01835-t004){ref-type="table"}).

3.4. Systematic Review {#sec3dot4-jcm-08-01835}
----------------------

A flow chart ([Supplementary Figure S2](#app1-jcm-08-01835){ref-type="app"}) describes study identification, screening, and inclusion. Three clinical trials, as well as four observational studies that investigated the association of interest, met the inclusion criteria. Due to differences in assessments and definitions of the outcome, data could not be pooled ([Table 5](#jcm-08-01835-t005){ref-type="table"}). Details of the results of the systematic review are provided in the [Supplementary Materials](#app1-jcm-08-01835){ref-type="app"}.

4. Discussion
=============

In this population-based cohort study, we observed that *ADRB2* polymorphisms: rs1042713 and rs1042714 were associated with a reduced risk of COPD exacerbation in current users of inhaled β~2~-agonists. Also, among current users of β~2~-agonist, carriers of the Arg16/Gln27 haplotype had a significantly lower risk of COPD exacerbation compared to those with the Gly16/Glu27 haplotype.

To the best of our knowledge, this is the first population-based study assessing the association between *ADRB2* polymorphisms and COPD exacerbations in patients with COPD treated with inhaled β~2~-agonists. In a substudy of the POET-COPD trial \[[@B7-jcm-08-01835]\] a one year randomized, double-blind, and double-dummy trial found that amongst patients treated with salmeterol, those with the Arg/Arg genotype of rs1042713 had a reduced risk of COPD exacerbations compared to patients with the Arg/Gly and Gly/Gly genotypes which is in line with our findings \[[@B7-jcm-08-01835]\]. However, the findings of other clinical trials \[[@B5-jcm-08-01835],[@B8-jcm-08-01835]\] showed no significant associations between *ADRB2* polymorphisms and the number of COPD exacerbations in LABA users \[[@B5-jcm-08-01835],[@B8-jcm-08-01835]\]. The clinical trials which were included in our systematic review \[[@B5-jcm-08-01835],[@B7-jcm-08-01835],[@B8-jcm-08-01835]\] ([Table 5](#jcm-08-01835-t005){ref-type="table"}) investigated the effect of *ADRB2* polymorphism and the risk of COPD exacerbations in patients exposed to LABA whereas we assessed the effect of *ADRB2* polymorphisms among inhaled β~2~-agonists users irrespective whether this was a SABA or a LABA. In a sensitivity analysis, we investigated this association in LABA users only and similar findings as for the main analysis were observed, although these results were no longer statistically significant; this, in turn, can be explained by the small sample size in this particular treatment category. A recent observational study, in spirometry-confirmed COPD patients, examined the associations between *ADRB2* polymorphisms (Arg16Gly and Gln27Glu) and risk of severe COPD exacerbations. \[[@B20-jcm-08-01835]\]. The results of the study showed an increased risk of COPD exacerbations in carriers of Arg16 and Gln27 \[[@B20-jcm-08-01835]\]. However, the proportion of COPD patients treated with LABA from the Copenhagen General Population Study was low (9.8%) \[[@B20-jcm-08-01835]\] particularly in comparison to our finding that revealed a protective effect in the category of current users of inhaled β~2~-agonists. So far, a few studies have examined the association between *ADRB2* haplotypes and response to β~2~-agonist \[[@B9-jcm-08-01835],[@B21-jcm-08-01835],[@B23-jcm-08-01835]\]. A study in Egypt \[[@B21-jcm-08-01835]\] of patients with COPD (*n* = 61), assessed the association between *ADRB2* haplotypes and COPD exacerbations. In contrast to our findings, they showed that the Arg16 genotypes and haplotype were associated with frequent COPD exacerbations. However, not all of COPD patients in this study were on regular β~2~-agonist treatment (88% exposed), and the definition used for COPD exacerbations was not provided \[[@B21-jcm-08-01835]\].

To summarize, a number of studies have assessed the effect of *ADRB2* polymorphisms on treatment response to β~2~-agonists with inconsistent results \[[@B5-jcm-08-01835],[@B6-jcm-08-01835],[@B7-jcm-08-01835],[@B8-jcm-08-01835],[@B9-jcm-08-01835],[@B20-jcm-08-01835],[@B21-jcm-08-01835],[@B22-jcm-08-01835],[@B23-jcm-08-01835],[@B24-jcm-08-01835],[@B25-jcm-08-01835]\]. Variation in the results might be related to differences in the study populations, study designs, ethnicity, outcome definitions, treatment classifications, concomitant drugs, as well as power-related issues due to different sample sizes.

The mechanism by which *ADRB2* polymorphisms confer risk for COPD exacerbations in patients treated with inhaled β~2~-agonists is still unknown. Green et al. conducted in-vitro experiments in human airway smooth muscle cells and showed that cells expressing Arg allele at rs1042713 in *ADRB2* underwent less downregulation in response to long-term β~2~-agonist exposure compared to cells expressing Gly allele at this position in *ADRB2* \[[@B26-jcm-08-01835]\]. This is in line with our findings showing a reduced risk of COPD exacerbations in carriers of the Arg allele treated with β~2~-agonist.

In contrast to COPD, previous studies in asthmatic patients suggested that the Arg allele (A) of rs1042713 was associated with an increased risk of asthma exacerbations in children and young adults \[[@B27-jcm-08-01835],[@B28-jcm-08-01835]\]. Indeed, COPD and asthma have been defined as two distinct diseases. COPD is characterized by persistent respiratory symptoms while in asthma, respiratory symptoms vary over time and also in intensity \[[@B1-jcm-08-01835],[@B29-jcm-08-01835]\]. Furthermore, exacerbations are typically triggered by allergens and infections in patients with asthma and COPD, respectively. \[[@B1-jcm-08-01835],[@B29-jcm-08-01835]\] However, it is still unclear how the SNP would be differently associated with exacerbations in patients with COPD compared to asthmatic patients.

The strengths of the Rotterdam Study are the prospective, population-based cohort design with an extended follow-up. Data were prospectively collected through consistent procedures for all subjects, independent of research questions or upcoming diseases, which made it less prone to selection and information bias.

A potential limitation of our study is the fact that spirometry data were only available from 2002 onwards. Therefore, it could result in an underestimation of asymptomatic COPD in the Rotterdam Study before January 2002. In addition, reversibility tests were not performed which might lead to an overestimation of the prevalence of COPD \[[@B30-jcm-08-01835],[@B31-jcm-08-01835]\]. To overcome this limitation, patients with asthma diagnosis were identified and excluded \[[@B12-jcm-08-01835]\]. Furthermore, smoking status was assessed at the time of visiting the center and not at the index date, implying potential misclassification of smoking status; however, smoking status was categorized into ever and never-smokers. Misclassification would only occur if non-smokers start to smoke during follow-up, which is unlikely in COPD patients. Also, we might have overestimated the use of β~2~-agonists as the exposure was based on dispensing data and not on actual intake. We obtained haplotype frequency estimates using the expectation-maximization (E-M) algorithm. Despite some concerns regarding the accuracy of the methods using phase-unknown data, previous studies have confirmed the usefulness of the haplotype approach \[[@B32-jcm-08-01835]\] and the validity of the statistical technique \[[@B33-jcm-08-01835]\] based on phase-unknown data of unrelated individuals. Moreover, as gene expression and eQTL are tissue-specific, in an optimal setting, they should be examined in lung tissue of COPD patients treated with inhaled β~2~-agonists.

In conclusion, we demonstrated that the Arg16/Gln27 haplotype in *ADRB2* was associated with a reduced risk of exacerbation in COPD patients treated with inhaled β~2~-agonists. However, further research is needed to confirm these findings.
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![*ADRB2* haplotypes and the risk of COPD exacerbations in current users of β~2~-agonists. The effect of Arg16/Gln27 and Gly16/Gln27 haplotypes compared to the effect of Gly16/Glu27 haplotype. The analyses were adjusted for age, sex, smoking, use of inhaled corticosteroids, and the daily dose of β~2~-agonists.](jcm-08-01835-g001){#jcm-08-01835-f001}

![*ADRB2* haplotypes and the risk of COPD exacerbations in current users of β~2~-agonists (smokers only). The effect of Arg16/Gln27 and Gly16/Gln27 haplotypes compared to the effect of Gly16/Glu27 haplotype. The analyses were adjusted for age, sex, use of inhaled corticosteroids, and the daily dose of β~2~-agonists.](jcm-08-01835-g002){#jcm-08-01835-f002}

jcm-08-01835-t001_Table 1

###### 

Baseline characteristics of COPD subjects.

  Characteristics                           COPD Subjects
  ----------------------------------------- ---------------
  *n*                                       1053
  Age (years), mean (SD)                    69.6 ± 9.0
  Sex (Male), no. (%)                       601 (57.1)
  Ever smoker \*, no. (%)                   891 (84.6)
  Status at the end of follow up, no. (%)   
  Individuals with COPD exacerbation        842 (80.0)
  Individuals without COPD exacerbation     211 (20.0)
  BMI kg/m^2^, median (IQR)                 25.9 (4.7)
  Heart failure, no. (%)                    82 (7.8)
  Coronary heart diseases, no. (%)          132 (12.5)
  Hypertension \*, no. (%)                  575 (54.6)
  Diabetes mellitus, no. (%)                83 (7.9)
  Minor allele (A) frequency (rs1042713)    0.35
  rs1042713 genotype, no. (%)               
  Arg/Arg (AA)                              134 (12.7)
  Arg/Gly (AG)                              473 (44.9)
  Gly/Gly (GG)                              446 (42.4)
  Minor allele (G) frequency (rs1042714)    0.47
  rs1042714 genotype, no. (%)               
  Glu/Glu (GG)                              232 (22.0)
  Glu/Gln (GC)                              536 (50.9)
  Gln/Gln (CC)                              285 (27.1)
  Haplotypes frequency                      
  Gly16/Glu27                               0.48
  Arg16/Gln27                               0.35
  Gly16/Gln27                               0.17

SD: standard deviation; BMI: body mass index; IQR: Interquartile Range (the difference between 75th and 25th percentiles). \* Data were missing on smoking in two subjects and on hypertension in 146 subjects.

jcm-08-01835-t002_Table 2

###### 

*ADRB2* polymorphisms (per copy of the effect allele) and the risk of COPD exacerbations.

  Db SNP No. \*                                                      Effect Allele   Events ^1^   Crude Model         Adjusted Model                       
  ------------------------------------------------------------------ --------------- ------------ ------------------- ---------------- ------------------- --------------
  Total COPD Population (irrespective of inhaled β~2~-agonist use)                                                                                         
  rs1042713                                                          Arg ^2^         *n* = 842    0.93 (0.84--1.02)   NS               0.93 (0.84--1.02)   NS
  rs1042714                                                          Gln ^3^         *n* = 842    0.97 (0.88--1.06)   NS               0.97 (0.89--1.07)   NS
  Non-users of inhaled β~2~-agonist                                                                                                                        
  rs1042713                                                          Arg ^2^         *n* = 375    1.02 (0.88--1.18)   NS               0.98 (0.85--1.13)   NS
  rs1042714                                                          Gln^3^          *n* = 375    1.05 (0.91--1.21)   NS               1.05 (0.91--1.21)   NS
  Past users of inhaled β~2~-agonists                                                                                                                      
  rs1042713                                                          Arg ^2^         *n* = 154    0.96 (0.76--1.22)   NS               1.03 (0.81--1.31)   NS
  rs1042714                                                          Gln ^3^         *n* = 154    0.88 (0.70--1.11)   NS               0.97 (0.76--1.23)   NS
  Current users of inhaled β~2~-agonists                                                                                                                   
  rs1042713                                                          Arg ^2^         *n* = 313    0.70 (0.59--0.82)   3.1 × 10^−5^     0.70 (0.59--0.84)   9.2 × 10^−5^
  rs1042714                                                          Gln ^3^         *n* = 313    0.80 (0.69--0.94)   5.9 × 10^−3^     0.80 (0.69--0.94)   7.2 × 10^−3^

\* Seattle single nucleotide polymorphisms (SNPs) database number. ^1^ Events, COPD exacerbations; HR, Hazard ratio. ^2^ Arg (A) allele frequency: 0.35. ^3^ Gln (C) allele frequency: 0.53. NS; non-significant. Additive genetic model was used for analyses. In total COPD population; adjusted for age, sex, and smoking. In non and past-users of β~2~-agonist; adjusted for age, sex, smoking, and use of inhaled corticosteroids. In current-users; adjusted for age, sex, smoking, use of inhaled corticosteroids, and the daily dose of β~2~-agonists.

jcm-08-01835-t003_Table 3

###### 

*ADRB2* polymorphisms (per copy of the effect allele) and the risk of COPD exacerbations in COPD population in current-users of β~2~-agonists (smokers only).

  Db SNP No. \*   Effect Allele   Events ^1^   Crude Model         Adjusted Model                       
  --------------- --------------- ------------ ------------------- ---------------- ------------------- --------------
  rs1042713       Arg ^2^         *n* = 277    0.64 (0.53--0.77)   1.9 × 10^−6^     0.66 (0.55--0.80)   1.2 × 10^−5^
  rs1042714       Gln ^3^         *n* = 277    0.73 (0.62--0.86)   2.1 × 10^−4^     0.74 (0.63--0.87)   3.8 × 10^−4^

\* Seattle single nucleotide polymorphism (SNP) database number.^1^ Events, COPD exacerbations; HR, hazard ratio. ^2^ Arg (A) allele frequency: 0.35. ^3^ Gln (C) allele frequency: 0.53. Additive genetic model was used for analyses. The analyses were adjusted for age, sex, use of inhaled corticosteroids, and the daily dose of β~2~-agonists.

jcm-08-01835-t004_Table 4

###### 

*ADRB2* polymorphisms (per copy of the effect allele) and the risk of COPD exacerbations in current-users of SABA only or LABA only.

  Db SNP No. \*   Effect Allele   Events ^1^   Crude Models        Adjusted Models                       
  --------------- --------------- ------------ ------------------- ----------------- ------------------- --------------
  SABA only                                                                                              
  rs1042713       Arg ^2^         *n* = 205    0.73 (0.59--0.90)   2.9 × 10^−3^      0.72 (0.58--0.90)   3.0 × 10^−3^
  rs1042714       Gln ^3^         *n* = 205    0.81 (0.67--0.99)   3.6 × 10^−2^      0.80 (0.66--0.98)   3.0 × 10^−2^
  LABA only                                                                                              
  rs1042713       Arg ^2^         *n* = 85     0.73 (0.53--1.03)   7.1 × 10^−2^      0.70 (0.48--0.98)   4.0 × 10^−2^
  rs1042714       Gln ^3^         *n* = 85     0.91 (0.67--1.22)   0.525             0.92 (0.67--1.27)   0.631

\* Seattle single nucleotide polymorphism (SNP) database number. ^1^ Events, COPD exacerbations; SABA, short-acting β~2~-agonists; LABA, long-acting β~2~-agonists; HR, Hazard ratio. ^2^ Arg (A) allele frequency: 0.35. ^3^ Gln (C) allele frequency: 0.53. Additive genetic model was used for analyses. Adjusted model: adjusted for age, sex, use of inhaled corticosteroids, the daily dose of β~2~-agonists and smoking.
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###### 

Overview of the studies included in the review.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (Year)                                           Design                                                Study Population                                                                                      Country                                Treatment                                           Outcome                                                                                                             Definition of COPD Exacerbation                                                                                          SNP(s)       Estimate/Association
  ------------------------------------------------------ ----------------------------------------------------- ----------------------------------------------------------------------------------------------------- -------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ------------ -------------------------------------------------------------------------------------------------------------------------------------------
  All participants were on β~2~-agonists treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Rabe et al.\                                           Randomized controlled trial                           2561 COPD patients with a history of smoking                                                          Multi-center in 25 countries           Salmeterol plus inhaled corticosteroids             Time to first COPD exacerbation; Kaplan-Meier curves were produced and the log-rank test was used for comparison.   Need of antibiotics or systemic glucocorticoids or admission to hospital                                                 rs1042713\   rs1042713:\
  (2014) \[[@B7-jcm-08-01835]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              rs1042714    Arg16Arg genotype was associated with reduced risk of exacerbation compared to Gly16Gly and Arg16Gly genotypes\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          rs1042714: no association

  Bleeker et al.\                                        Two randomized controlled trials                      Study 1, 1456 Study2, 1383 COPD patients with a history of smoking                                    Multi-center (US, Europe and Mexico)   Formoterol only or in combination with budesonide   Number of COPD exacerbations per patient-treatment year                                                             Need of oral corticosteroid treatment or hospitalization                                                                 rs1042713    No association between rs1042713 genotypes and number of COPD exacerbations per patient-treatment year
  (2012) \[[@B8-jcm-08-01835]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Yelensky et al.\                                       Retrospective analysis of phase III clinical trials   565 COPD patients with a history of smoking                                                           USA                                    Patients treated with Indacaterol for 26 weeks      Number of COPD exacerbations during the 26-week of treatment; using Poisson regression                              Need of systemic glucocorticoid therapy, antibiotics, oxygen treatment and/or hospitalization or emergency room visit.   rs1042711\   No association between the SNPs and number of COPD exacerbations.
  (2012) \[[@B5-jcm-08-01835]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              rs1042713\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             rs1042714\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             rs1800888    

  Not all participants were on β~2~-agonists treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Ingebrigtsen et al.\                                   Prospective cohort                                    5219 COPD patients and 85.3% of them had a history of smoking (Copenhagen General Population Study)   Denmark                                9.8 % of COPD patients were on LABA treatment       Time to first exacerbation;\                                                                                        As acute admissions with a discharge diagnosis of COPD                                                                   rs1042713\   The Arg allele at rs1042713 and the Gln allele at rs1042714\
  (2019) \[[@B20-jcm-08-01835]\]                                                                                                                                                                                                                                                                                by using univariable\                                                                                                                                                                                                                        rs1042714    were associated with an increased risk of COPD exacerbations
                                                                                                                                                                                                                                                                                                                competing risks regression analyses                                                                                                                                                                                                                       

  Hussein et al.\                                        Case-control study                                    61 COPD patients with a history of smoking, (recruited from three hospitals)                          Egypt                                  88% of patients were on β~2~-agonists treatment     Number of exacerbations                                                                                             No definition for COPD exacerbation                                                                                      rs1042713\   rs1042713: Arg16 genotypes and haplotypes were associated with more frequent exacerbations.
  (2017) \[[@B21-jcm-08-01835]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             rs1042714    

  Emeryk-Mksymiuk et al.\                                Retrospective study                                   92 COPD patients with a history of smoking, (recruited from outpatient clinic)                        Poland                                 83% of patients were on β~2~-agonists treatment     Self-reported exacerbations                                                                                         Need of antibiotic therapy, systemic glucocorticoid therapy or hospitalization                                           rs1042713\   rs1042713: patients with Arg/Arg genotype required more frequent treatment with antibiotics, as well as systemic corticosteroid therapy.\
  (2017) \[[@B6-jcm-08-01835]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              rs1042714    rs1042714: no association

  Vacca et al.\                                          Case-control study                                    190 COPD patients with a history of smoking (recruited from two centers)                              Germany                                No information on β~2~-agonist treatment            ≥3 exacerbations within the last 3 year vs no exacerbation within the last 2 years                                  Need of hospitalization                                                                                                  rs1042713\   rs1042713: no association reported\
  (2009) \[[@B22-jcm-08-01835]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             rs1042714    rs1042714: no association reported
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
